Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

FDA Approval: End of Arena, VIVUS Running Out of Adrenaline?

The celebrations must be over. That was fast. Arena Pharmaceuticals (NASDAQ:ARNA) and VIVUS Inc. (NASDAQ:VVUS), the two companies that have recently gained FDA approval for their weight-loss drugs – the first such drugs approved by the FDA this millennium – were celebrating their wins.

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)

But investors, apparently, haven’t seen much to celebrate, as the two company’s stocks have suffered in the days since the approvals were announced, and both company’s stocks were tumbling again Tuesday. At midday, Arena’s stock was down nearly 7 percent to $8.70 a share, while  VIVUS Inc was off 4.5 percent to $21.25.

The real question is, why are these stocks down so much today of all days? Both companies already released their earnings reports days ago, and the FDA approvals came earlier this month. This article explored a comparison between the two drugs and their parent companies to try to give some clues.

Well, it seems to be mystery, though some theories are floating. Once article discussing Arena Pharmaceuticals announced that the company was transferring its U.S. Belviq application to Eisai, essentially washing its hands of marketing and regulatory issues involving Belviq. What is interesting is that this transfer didn’t apply to the rest of the world. However, to basically “hand off” the regulatory and marketing aspects of Belviq to another company seems to have dampened investor spirit in Arena, since Belviq is the first drug by Arena Pharmaceuticals approved for use and sale in the U.S. This partnership is certain to limit the amount of revenue Arena is to get from Belviq sales, which could be affecting investors’ opinions about the company.

With the case of VIVUS Inc, some of its news is old. Citron Research published a paper a couple weeks ago saying that Vivus stock is overvalued because of some patent-protection issues involving its weight-loss drug, Qsymia (also called Qnexa). This recent article goes into detail about the patent issue, saying the report is legally misleading and wore, inaccurate. But why is the stock falling instead of rising? If the patent issues are not credible, and Vivus has no partnership agreements that could limit its profits when Qsymia hits the market, why would this company suffer?

The one working theory might be the risk involved with these companies moving their drugs to market at a time when Pfizer’s patent on its popular cholesterol drug Lipitor has expired. With that expiration (as reported in Pfizer’s earnings report Tuesday morning), the market may soon fill up with generic alternatives to that popular drug, which likely means more competition in the marketplace for both Belviq and Qsymia. With that risk, along with all the money the companies invested into their drugs, investors perhaps think the companies will be hard-pressed to sell the drugs at the price-point they would need.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.